

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

RESIGNATION OF DIRECTOR AND PROPOSED APPOINTMENT OF DIRECTOR

RESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of CanSino Biologics Inc. (the “**Company**”) hereby announces that, Dr. Zheng YIN (“**Dr. Yin**”) has tendered his resignation as a non-executive Director of the Company and a member of the audit committee under the Board (the “**Audit Committee**”), with effect from the conclusion of the 2018 annual general meeting (the “**AGM**”) of the Company proposed to be held on or before June 30, 2019, due to his other work commitments.

Dr. Yin confirms that there is no disagreement between him and the Company, the Board, the Audit Committee and the board of supervisors of the Company, respectively, and there are no other matters relating to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to take this opportunity to thank Dr. Yin for his valuable contributions to the Company during his term of office.

PROPOSED APPOINTMENT OF DIRECTOR

The Board of the Company announces that Mr. Zhi XIAO (肖治) (“**Mr. Xiao**”) is nominated as a candidate for non-executive Director of the first session of the Board and member of the Audit Committee. The nomination of Mr. Xiao will be submitted to the AGM for consideration and approval.

Biographical details of Mr. Xiao are set out as follows:

Mr. Zhi XIAO (肖治), aged 41, has been the managing director of SDIC Fund Management Co., Ltd. (國投創新投資管理有限公司) since 2016. Mr. Xiao has been serving as a director of Zhejiang Novus Pharmaceuticals Co., Ltd. (浙江創新生物有限公司), a director of Dizal (Jiangsu) Pharmaceutical Co., Ltd. (迪哲(江蘇)醫藥有限公司), a director of TINAVI Medical Technologies Co., Ltd. (北京天智航醫療科技股份有限公司) (a company delisted from the National Equities Exchange and Quotations on April 1, 2019), and an independent non-executive director of Guangdong Great River Smarter Logistics Co., Ltd. (廣東宏川智慧物流股份有限公司) (a company listed on the Shenzhen Stock Exchange, stock code: 002930). Mr. Xiao received his bachelor's degree in veterinary medicine from China Agricultural University and his master of business administration degree from Tsinghua University.

Mr. Xiao's term of office shall commence from the date of approval at the AGM until the expiry of the term of the first session of the Board. He shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a service contract with Mr. Xiao upon approval at the AGM. As a non-executive Director, Mr. Xiao will not receive any director's fee or remuneration from the Company.

Save as disclosed above, Mr. Xiao does not hold any directorships in any listed companies in the past three years prior to the date of this announcement, does not hold any positions in the Company or any of its subsidiaries, and does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Xiao does not have any interest in the securities of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Mr. Xiao has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

Mr. Xiao has confirmed that there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company, and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

On behalf of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, May 10, 2019

As at the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Dr. Zheng YIN as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Dr. Luis BARRETO and Dr. Pierre Armand MORGON as independent non-executive Directors.